Nussdorfer G G, Malendowicz L K
Department of Anatomy, University of Padua, Italy.
Peptides. 1998;19(8):1443-67. doi: 10.1016/s0196-9781(98)00102-8.
Vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) are members of a family of regulatory peptides that are widely distributed in the body and share numerous biologic actions. The two peptides display a remarkable amino acid-sequence homology, and bind to a class of G protein-coupled receptors, named PACAP/VIP receptors (PVRs), whose signaling mechanism mainly involves the activation of adenylate-cyclase and phospholipase-C cascades. A large body of evidence suggests that VIP and PACAP play a role in the control of the hypothalamo--pituitary-adrenal (HPA) axis, almost exclusively acting in a paracrine manner, since their blood concentration is very low. VIP and PACAP are contained in both nerve fibers and neurons of the hypothalamus, and VIP, but not PACAP, is also synthesized in the pituitary gland. Both peptides are expressed in the adrenal gland, and especially in medullary chromaffin cells. All the components of the HPA axis are provided with PVRs. VIP and PACAP enhance pituitary ACTH secretion, VIP by eliciting the hypothalamic release of CRH and potentiating its secretagogue action, and PACAP by directly stimulating pituitary corticotropes. Through this central mechanism, VIP and PACAP may increase mineralo- and glucocorticoid secretion of the adrenal cortex. VIP but not PACAP also exerts a weak direct secretagogue action on adrenocortical cells by activating both PVRs and probably a subtype of ACTH receptors. VIP and PACAP raise aldosterone production via a paracrine indirect mechanism involving the stimulation of medullary chromaffin cells to release catecholamines, which in turn enhance the secretion of zona glomerulosa cells via a beta-adrenoceptor-mediated mechanism. PACAP appears to be able to evoke a glucocorticoid response through the activation, at least in the rat, of the intramedullary CRH/ACTH system. The relevance of these effects of VIP and PACAP under basal conditions is questionable, although there are indications that endogenous VIP is involved in the maintenance of the normal growth and steroidogenic capacity of rat adrenal cortex. However, indirect evidence suggests that these peptides might play a relevant role under paraphysiological conditions (e.g., in the mediation of HPA axis responses to cold and inflammatory stresses) or may be somehow involved in the pathogenesis of Cushing disease or some case of hyperaldosteronism associated with secreting pheochromocytomas.
血管活性肠肽(VIP)和垂体腺苷酸环化酶激活肽(PACAP)是一类调节肽家族的成员,它们广泛分布于体内并具有多种生物学作用。这两种肽显示出显著的氨基酸序列同源性,并与一类名为PACAP/VIP受体(PVRs)的G蛋白偶联受体结合,其信号传导机制主要涉及腺苷酸环化酶和磷脂酶-C级联反应的激活。大量证据表明,VIP和PACAP在控制下丘脑-垂体-肾上腺(HPA)轴中发挥作用,几乎完全以旁分泌方式起作用,因为它们的血液浓度非常低。VIP和PACAP存在于下丘脑的神经纤维和神经元中,并且VIP(而非PACAP)也在垂体中合成。这两种肽都在肾上腺中表达,尤其是在髓质嗜铬细胞中。HPA轴的所有组成部分都有PVRs。VIP和PACAP可增强垂体促肾上腺皮质激素(ACTH)的分泌,VIP通过引起下丘脑释放促肾上腺皮质激素释放激素(CRH)并增强其促分泌作用,而PACAP则通过直接刺激垂体促肾上腺皮质激素细胞来实现。通过这种中枢机制,VIP和PACAP可能会增加肾上腺皮质的盐皮质激素和糖皮质激素分泌。VIP(而非PACAP)还通过激活PVRs以及可能的ACTH受体亚型,对肾上腺皮质细胞产生微弱的直接促分泌作用。VIP和PACAP通过一种旁分泌间接机制提高醛固酮的产生,该机制涉及刺激髓质嗜铬细胞释放儿茶酚胺,进而通过β-肾上腺素能受体介导的机制增强球状带细胞的分泌。PACAP似乎能够通过激活(至少在大鼠中)髓内CRH/ACTH系统来引发糖皮质激素反应。尽管有迹象表明内源性VIP参与维持大鼠肾上腺皮质的正常生长和类固醇生成能力,但在基础条件下,VIP和PACAP这些作用的相关性仍存在疑问。然而,间接证据表明,这些肽可能在生理异常条件下(例如,在介导HPA轴对寒冷和炎症应激的反应中)发挥相关作用,或者可能以某种方式参与库欣病或某些与分泌性嗜铬细胞瘤相关的醛固酮增多症病例的发病机制。